Company: HROW
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009263
Chunk: 65

Company: HARROW, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 2
Chunk 65
---
armacies, outsourcing facilities, drug company and manufacturers, and otherwise fund our operations. We may also use our resources to
conduct clinical trials or other studies in support of our formulations or any drug candidate for which we pursue FDA approval, to pursue
additional development programs or to explore other development opportunities.

Net Cash Flow

The following provides detailed information about
our net cash flows for the three months ended March 31, 2025 and 2024:

    For the Three Months Ended
                                                                                March 31, 

    2025  
    2024 
  
    Net cash provided by (used in): 

     Operating activities 
    $19,668,000  
    $(4,628,000)
  
     Investing activities 
     (212,000) 
     (110,000)
  
     Financing activities 
     23,000  
     (809,000)
  
    Net change in cash and cash equivalents 
     19,479,000  
     (5,547,000)
  
    Cash and cash equivalents at beginning of the period 
     47,247,000  
     74,085,000 
  
    Cash and cash equivalents at end of the period 
    $66,726,000  
    $68,538,000 

Operating Activities

Net cash provided by (used
in) operating activities during the three months ended March 31, 2025 was $19,668,000 compared to $(4,628,000) during the same period
in the prior year. The increase in net cash provided by operating activities between the periods was mainly attributed to a decrease of
$39,196,000 in accounts receivable due to collections during the three months ended March 31, 2025 compared to a decrease of $8,396,000
during the same period in 2024.

Investing Activities

Net cash used in investing
activities during the three months ended March 31, 2025 was $(212,000) compared to $(110,000) during the same period in the prior year.
Cash used in investing activities in 2025 and 2024 was primarily related to equipment and software purchases.

Financing Activities

Net cash provided by (used
in) financing activities during the three months ended March 31, 2025 and 2024 was $23,000 and $(809,000), respectively. Cash provided